Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCAGet Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Price Performance

The stock has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.

Genocea Biosciences Company Profile

(Get Free Report)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Read More

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.